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Transplantation of adipose-derived stem cells (ADSCs) is an emerging therapeutic option for addressing intrac-
table diseases such as critical limb ischemia (CLI). Evidence suggests that therapeutic effects of ADSCs are pri-
marily mediated through paracrine mechanisms rather than transdifferentiation. These secreted factors can be 
captured in conditioned medium (CM) and concentrated to prepare a therapeutic factor concentrate (TFC) com-
posed of a cocktail of beneficial growth factors and cytokines that individually and in combination demonstrate 
disease-modifying effects. The ability of a TFC to promote reperfusion in a rabbit model of CLI was evaluated. 
A total of 27 adult female rabbits underwent surgery to induce ischemia in the left hindlimb. An additional five 
rabbits served as sham controls. One week after surgery, the ischemic limbs received intramuscular injections 
of either (1) placebo (control medium), (2) a low dose of TFC, or (3) a high dose of TFC. Limb perfusion was 
serially assessed with a Doppler probe. Blood samples were analyzed for growth factors and cytokines. Tissue 
was harvested postmortem on day 35 and assessed for capillary density by immunohistochemistry. At 1 month 
after treatment, tissue perfusion in ischemic limbs treated with a high dose of TFC was almost double (p < 0.05) 
that of the placebo group [58.8 ± 23 relative perfusion units (RPU) vs. 30.7 ± 13.6 RPU; mean ± SD]. This effect 
was correlated with greater capillary density in the affected tissues and with transiently higher serum levels of 
the angiogenic and prosurvival factors vascular endothelial growth factor (VEGF) and hepatocyte growth fac-
tor (HGF). The conclusions from this study are that a single bolus administration of TFC demonstrated robust 
effects for promoting tissue reperfusion in a rabbit model of CLI and that a possible mechanism of revascular-
ization was promotion of angiogenesis by TFC. Results of this study demonstrate that TFC represents a potent 
therapeutic cocktail for patients with CLI, many of whom are at risk for amputation of the affected limb.
Key words: Mesenchymal stem cells (MSCs); Stromal vascular fraction; 
Therapeutic factor concentrate (TFC); Critical limb ischemia (CLI); Rabbit
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INTRODUCTION
The nonadipocyte stromal vascular fraction (SVF) of 
human adipose tissues contains a population of mesenchy-
mal stem cells (MSCs) intimately associated with blood 
vessels1. These adipose-derived stem cells (ADSCs) pos-
sess many phenotypic and functional similarities to bone 
marrow-derived MSCs (BM-MSCs). Unlike BM-MSCs, 
though, multipotent ADSCs can be harvested at rela-
tively high numbers (0.5 × 106/g fat with a typical harvest 
of 500 g of tissue) using minimally invasive techniques 
of lipoaspiration or lipectomy of subcutaneous adipose 
tissue2. ADSCs rapidly proliferate in culture, allowing 
fast expansion to obtain cell quantities sufficient to treat 
large volume lesions. Transplantation of ADSCs is an 
emerging therapeutic option for addressing many intrac-
table diseases, including cardiovascular diseases such as 
peripheral artery disease (PAD)3–8.
Evidence suggests that the therapeutic effects of 
MSCs, including ADSCs, are primarily mediated through 
paracrine mechanisms rather than cellular transdiffer-
entiation9–12. The three predominant paracrine actions 
of stem cell-secreted factors are (1) trophic support of 
survival and repair of cells in diseased or injured 
tissues, (2) modulation of the immune system, and (3) 
recruitment of endogenous stem and progenitor cells11. 
Trophic factors produced by ADSCs include the potent 
paracrine prosurvival and proangiogenic proteins hepa-
tocyte growth factor (HGF) and vascular endothelial 
growth factor (VEGF) that reduce cell death and promote 
reperfusion of ischemic tissues. The immunomodulatory 
factors secreted by ADSCs, such as prostaglandin E2 
(PGE2), tumor necrosis factor-inducible gene 6 protein 
(TSG-6), and interleukin-10 (IL-10), support reduction 
of inflammation and suppression of T-cell pathology. 
This, in turn, suppresses atherothrombotic circulatory 
defects in the lower extremities in diabetic patients with 
diabetic foot ulcers and the most severe form of PAD—
critical limb ischemia (CLI)13. Chemotactic factors, such 
as stromal cell-derived factor-1a (SDF-1a)14, attract 
circulating stem and progenitor cells to the injury site 
where they support regeneration of damaged tissues15. 
Moreover, these factors have the potential to work in 
concert to affect physiological improvements in diseased 
and injured tissues. The contribution of secreted factors 
to ADSC potency was established by knocking down 
HGF expression using a stably integrated small interfer-
ing RNA construct, which severely attenuated ADSC-
mediated promotion of ischemic limb revascularization 
in a mouse model of CLI16.
Paracrine-mediated effects explain the frequently 
reported functional benefits of MSC treatment in the 
absence of stable cell engraftment on the scale required 
to replace significant portions of injured tissues. Given 
that each cell secretes a number of different factors that 
function to modulate a spectrum of molecular pathways 
required for preserving tissues and correcting disease, 
paracrine effects have the benefit over direct tissue 
replacement of amplifying the effects of cell treatment. 
Each cell produces an abundance of these factors, and 
even brief exposure to target tissues preceding clear-
ance is sufficient to produce therapeutic effects. Thus, a 
paracrine mechanism of action overcomes limitations in 
numbers of recoverable and deliverable therapeutic cells 
through amplification of the effect produced by each cell; 
conversely, direct tissue replacement by multipotent stem 
cells requires a sufficient number of cells to stably engraft 
and replace each cell type lost due to the insult.
Recognition that the functional component of adult 
stem cells may be attributable to secreted factors led 
our group and others to explore the potential therapeu-
tic benefit of delivering these factors in the absence of 
cells10,17–20. ADSC-derived paracrine factors can be cap-
tured by briefly (up to 72 h) incubating freshly isolated 
or culture-expanded ADSCs in minimal medium lacking 
added protein supplements20. Incubation conditions are 
not permissive for cell growth; however, ADSCs remain 
viable and “condition the medium” by secreting para-
crine factors. The resulting therapeutic factor concentrate 
(TFC), composed of a cocktail of beneficial growth fac-
tors and cytokines, is filtered to remove all cells and then 
concentrated before storage by freezing.
The potential for modifying disease status through 
treatment with the array of paracrine factors present in 
TFC may offer advantages over cellular therapies. First, 
there is reduced concern regarding maintaining cell via-
bility during preparation of cryopreserved cells for injec-
tion. Additionally, because of their size, cells possess a 
potential risk of embolization. Conversely, stem cells, 
such as ADSCs, have the potential to home to target tis-
sues and produce a greater local concentration of para-
crine factors, although targeted effects will be limited in 
duration due to rapid clearance of most cells within the 
first 24 h following administration21,22.
The purpose of the present study was to test the effi-
cacy of a single intramuscular administration of human 
TFC (hTFC) in the experimental setting of the rabbit sub-
acute CLI model. A positive result could open up the pos-
sibility of subsequent clinical studies designed to evaluate 
TFC as a novel therapy for CLI.
MATERIALS AND METHODS
Human and Animal Research Approval
Collection of adipose tissues and blood from human 
volunteers was approved by the Ethics Committee of 
FN Ostrava (Approval No. 654/2014). All procedures 
involving animals were approved by the Local Bioethics 
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Commission of the Polish Academy of Science, Kraków, 
Poland (Approval No. 1103/2014).
ADSC Isolation and Culture
ADSCs were isolated from adipose tissue by Cytori 
Celution CRS 800 (Cytori Therapeutics Inc., San Diego, 
CA, USA). Adipose tissue was obtained with written 
informed consent from a single male patient [40 years 
of age and body mass index (BMI) of 54] undergoing 
elective lipoplasty at the University Hospital Ostrava. 
Erythrocytes in the obtained cell suspension were lysed 
with red blood cell (RBC) lysis buffer (eBioscience, San 
Diego, CA, USA). The number and viability of cells were 
determined by 0.4% trypan blue solution staining (Sigma-
Aldrich, St. Louis, MO, USA) and Burker’s chamber 
counting method. Cells were seeded in cell culture flasks 
(Nunc, Rochester, NY, USA) at density of 1 × 104 cells/
cm2 in endothelial cell growth medium (EGM)-2MV 
(Lonza, Valais, Switzerland) supplemented with 5% (v/v) 
fetal bovine serum (FBS; Hyclone, Logan, UT, USA). 
Cell cultures were maintained at 37°C in a humidified 
atmosphere containing 5% CO2. This initial passage of 
the primary cell culture was designated passage 0 (P0). 
After 24 h, the medium was changed to remove nonad-
herent cells. When 70% confluence was reached, cells 
were detached using CTS TrypLE Select Enzyme (Gibco, 
Paisley, Scotland, UK) and replated at a density of 5 × 103 
cells/cm2 (P1). Cells were expanded by passaging repeat-
edly until P5. Viable nucleated cell counts were obtained 
using a Luna-STEM™ automated cell counter (Logos 
Biosystems, Annandale, VA, USA) according to the man-
ufacturer’s instructions.
ADSC Conditioned Medium (ADSC-CM) and TFC
ADSCs (P6) were seeded into 225-cm2 culture flasks 
(Corning, Inc., Corning, NY, USA) at a density of 1 × 104 
cells/cm2 in cultivation media. When reaching 80% con-
fluence, cells were rinsed three times with Dulbecco’s 
phosphate-buffered saline (DPBS; Gibco), and Dulbecco’s 
modified Eagle’s medium (DMEM; Lonza) was applied 
to the cells for 48-h conditioning at 37°C in a humidified 
atmosphere containing 10% CO2. At the end of incuba-
tion, the conditioned medium was harvested, centrifuged 
at 1,000 × g to remove debris and detached cells, con-
centrated 50-fold using Vivacell 70 (10 kDa; Sartorius, 
Goettingen, Germany), and stored at −80°C. All studies 
were performed with concentrated TFC.
Flow Cytometry
The cell suspension product from the Celution iso-
lation device was analyzed by flow cytometry for cell 
surface marker expression. Cells (2 × 105) were added 
to tubes containing complete medium (100 μl) on ice. 
Fluorescently conjugated monoclonal antibodies to cell 
surface markers or isotype controls (1 μl) were added 
to the tubes and incubated for 20–30 min on ice. Cells 
were subsequently washed with PBS, fixed in para-
formaldehyde (PFA; Tousimis Research Corporation, 
Rockville, MD, USA), and analyzed using a Cytomics 
FC500 (Beckman Coulter, Brea, CA, USA). The follow-
ing antibody conjugates (Beckman Coulter, Brea, CA, 
USA) were used: CD34-phycoerythrin (PE) (catalog 
#A0776); CD34-fluroscein isothiocyanate (FITC) (cata-
log #IM1870); CD34-PE/Cy5 (PC5) (catalog #A07777); 
CD10-FITC (catalog #IM0471U); CD29-PE (catalog 
#6604159); CD31-PE (catalog #IM2409); CD45-FITC 
(catalog #A07782); CD49-FITC (catalog #IM1425); 
CD73-PE (catalog #344003); CD90-FITC (catalog 
#IM1893U); CD105-PE (catalog #A07414); CD13-PE/
CD14-FITC (catalog #A07722); and IgG1 isotype control- 
PE/FITC (catalog #A07794).
Characterization of TFC
The concentrated TFC from ADSCs was analyzed 
using Quantibody multiplex enzyme-linked immuno-
sorbent assays (ELISAs) (RayBiotech Inc., Norcross, GA, 
USA) for the presence of multiple growth factors, includ-
ing acidic fibroblast growth factor (aFGF), insulin-like 
growth factor 1 (IGF-1), platelet-derived growth factor AA 
(PDGF-AA), transforming growth factor-b1 (TGF-b1), 
VEGF, interferon-g (IFN-g), IL-1b, IL-2, IL-4, IL-6, IL-7, 
IL-8, IL-10, IL-12 p70, IL-13, brain-derived neurotrophic 
factor (BDNF), matrix metalloproteinase-9 (MMP-9), and 
tumor necrosis factor-a (TNF-a). For comparison, human 
serum obtained from a healthy volunteer unrelated to the 
adipose tissue donor was also analyzed. Fluorescence sig-
nals from the membranes (arrays) were collected using 
a SureScan Microarray Scanner (Agilent Technologies, 
Santa Clara, CA, USA) and evaluated using software from 
RayBiotech Inc.
Animals
Animal studies were approved by the Second Local 
Ethical Committee on Animal Testing at the Institute of 
Pharmacology of the Polish Academy of Science, Cracow, 
Poland (Resolution No. 1103/2014).
A total of 32 female New zealand white rabbits 
(3.5 months, 2.7 ± 0.2 kg) were purchased from zakład 
Doświadczalny Instytutu zootechniki PIB (Chorzelów, 
Poland). The environmental controls on temperature and 
humidity were set according to the Center for Cardio-
vascular Research and Development (Kostkowice, Poland) 
standards for animal care. Animals were acclimated for 
28 days prior to beginning the study. A sufficient amount 
of feed was offered for maintenance, and water was sup-
plied ad libitum. Each rabbit had a unique ID number. 
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Body weights were recorded upon receipt and weekly 
thereafter until the end of the study. The most recent body 
weight was used for calculation of all perioperative medi-
cations. Body temperature was measured using a rectal 
probe thermometer.
Hindlimb Ischemia Surgery
At day 0, rabbits were anesthetized with an intramus-
cular injection of 100 mg/kg ketamine and 20 mg/kg 
xylazine (Vetoquinol, Gorzów Wielkopolski, Poland) and 
subcutaneous injection of 0.5 mg/kg atropine (Warszawie 
zakłady Farmaceutyczne Polfa, Warszawa, Poland). Sur-
gical and ligation/excision were conducted to establish 
ischemia in the left hindlimb. The femoral artery and its 
branches as well as femoral vein were ligated, beginning 
from the inguinal ligament to the bifurcation of saphe-
nous and popliteal arteries and excised. The incision was 
closed with 3-0 silk sutures. A sham group underwent the 
same surgery without ligation or excision of the artery 
and vein.
Study Groups and Treatments
Rabbits with induced limb ischemia were randomly 
assigned to one of three treatment groups (nine/group): 
(1) placebo control (unconditioned DMEM), (2) low-dose 
TFC, and (3) high-dose TFC. Treatments were provided to 
animals on day 7 after surgery by intramuscular injection 
using a 1-ml luer-lock syringe with a 0.45 × 13-mm needle. 
The doses of placebo or TFC were divided into five injec-
tion sites: two into each bundle of the m. gastrocnemius 
(four injections) and one into the m. tibialis anterior. The 
volume of injection per site was 0.4 ml for placebo and 
low-dose TFC and 0.8 ml for high-dose TFC.
Laser Doppler Perfusion
Perfusion status of the ischemic (left) and intact 
(right) limbs was assessed with a Laser Doppler Perfilux 
5000 device (Perimed AB, Järfälla, Sweden) on days 0 
(before and after the surgery), 14, 28, and 35. Perfusion in 
ische mic hindlimbs immediately following surgery was 
approximately 20% of presurgery levels.
Rabbit Serum Analysis for Proteins
Venous blood (4–5 ml) was collected from the auric-
ular vein; serum was obtained and frozen for later use. 
Serum samples were analyzed for multiple rabbit growth 
factors by ELISA: HGF, granulocyte macrophage colony- 
stimulating factor (GM-CSF), VEGF, basic fibroblast 
growth factor (bFGF), glial cell-derived neurotrophic 
factor (GDNF), SDF-1a, and TGF-b (all kits were pur-
chased from BlueGene Biotech, Shanghai, China).
Necropsy and Histological Examination
After the final Doppler assessment on day 35, the rab-
bits, while under general anesthesia, were euthanized by 
intravenous injection of pentobarbital (Biowet Puławy, 
Puławy, Poland) euthanasia solution. After death, the 
tibialis anterior and gastrocnemius muscles were har-
vested for evaluation. The tibialis anterior muscle was 
immediately frozen by placing on dry ice. Gastrocnemius 
muscles were marked for orientation and fixed in 10% 
formaldehyde (Bio-Optica Milano, Milan, Italy). Both 
muscles were photographed, and their size was mea-
sured. The fixed muscles were grossly (0.3–0.5 cm 
thick) dissected from the broadest part of the proximal 
muscle region. Sections were divided into four pieces and 
enclosed into bioptic sectors in the direction from medial 
to lateral side.
Tissue segments were embedded in paraffin, and 
paraffin blocks were sectioned at 2- to 4-μm thickness 
and stained with hematoxylin and eosin (H&E; Merck, 
Kenilworth, NJ, USA). After examination of H&E-
stained sections to confirm tissue integrity, additional sec-
tions were processed for immunohistochemical analyses. 
Antibodies used were CD31 (1:20; DakoCytomation, 
Glostrup, Denmark) and a-smooth muscle actin (aSMA; 
1:100; DakoCytomation). The numbers of positively 
staining vessels in a 10-mm2 area of each block were 
counted. Capillary density measurements were normal-
ized by subtracting the values from the nonischemic limb 
from the ischemic limb. Thus, the values range from both 
positive to negative.
Data Representation and Statistical Analyses
Data were analyzed with open source R (R-project, 
The R Foundation for Statistical Computing, Vienna, 
Austria) and Matlab (MathWorks, Natic, MA, USA) 
institutional license software. Reported summary statis-
tics are arithmetic mean with 1 standard deviation (SD), 
denoted as mean ± SD. Most of the measurements are 
Table 1. Characteristics of Stromal Vascular Fraction (SVF) and ADSC 
Suspensions Obtained With the Luna-STEM™ Automated Cell Counter
Cell Counter Results Fresh SVF P2 P3 P5
Total nucleated cells (×106 cells/ml) 3.62 1.72 2.19 1.84
Viability of nucleated cell (%) 64.6 85.0 96.8 94.0
Average nucleated cell size (μm) 8.9 19.6 16.9 16.2
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shown as box and whisker plots (box plot) to account for 
strong non-Gaussianity of much of the data. On each box, 
the central mark is the median; the top and bottom edges 
of the box are the 75th and 25th percentiles, respectively; 
and the whiskers extend to the most extreme data points 
not considering outliers, which are marked with the black 
dots. To test the key statistical hypotheses about the treat-
ment groups for all the endpoints, Kruskal–Wallis test, 
Mann–Whitney U test, and Welch’s t-test were calcu-
lated, reported, and selected according to their suitability 
for the particular statistical properties (probability density 
moments) of the distributions of the measurements being 
compared. In addition to classical statistics, an alterna-
tive approach of gnostics23,24 was used here to analyze and 
validate our findings.
RESULTS
Preparation and Characterization of TFC
Approximately 3.62 × 106 total nucleated cells/ml were 
obtained from 70 ml of lipoaspirate (Table 1). Freshly 
harvested cells had a typical morphology and surface 
marker profiles of SVF cells (Fig. 1 and Table 2) and 
ADSCs. These cells were expanded to P5 and were simi-
lar to ones that were previously reported2 (Table 2 and 
Fig. 2). Levels of selected angiogenic and inflammatory 
cytokines and growth factors in 50-fold concentrated TFC 
were compared to those of human serum (Table 3). While 
the concentrations of the majority of proteins were similar 
between TFC and human serum, the levels of VEGF, IL-6, 
and IL-8 were >10-fold higher in TFC. Conversely, levels 
of MMP-9, IL-7, and PDGF-AA were much lower in TFC 
compared to serum.
Characterization of the Hindlimb Ischemia Model
A total of 32 animals were originally enrolled in the 
study. A total of eight rabbits died before the end of the 
study; five were found dead or had to be euthanized as a 
result of complications due to the surgery before admin-
istration of the therapeutic agent, and two died after 
administration of TFC or placebo. Early deaths were in 
sham (one rabbit), placebo (two rabbits before adminis-
tration and one after), and low-dose TFC (three rabbits 
before administration) and high-dose TFC (one rabbit 
after administration) groups. In an attempt to rebalance 
the group numbers, one rabbit from the control group and 
one rabbit from the high-dose TFC group were reassigned 
to the middle dose group before administration. The num-
ber of rabbits (in parentheses) in each group surviving to 
the end of the study were as follows: sham group (four), 
placebo (five), low-dose TFC (eight), and high-dose TFC 
(seven). There were no differences between groups in 
body temperatures or weights (data not shown).
TFC Augments Reperfusion in Part by 
Stimulating Angiogenesis
Blood perfusion in the left ischemic and right intact 
limbs was determined immediately pre- and postsurgery 
and at 2, 4, and 5 weeks after surgery. Sham animals dis-
played very little change in blood perfusion during this 
period (Fig. 3). Trends toward greater perfusion in the 
Figure 1. Morphology of stromal vascular fraction (SVF) cells. 
Image from Luna-STEM™ automated cell counter showing 
morphology of cells obtained from SVF. The green marking 
corresponds to live cells, and the red coloring highlights dead 
cells. Counted cells are encircled with red and green lines for 
dead and live cells, respectively. Scale bar: 50 mm.
Table 2. Characterization of Cell Composition of Freshly Obtained SVF and 
Cultured ADSCs at Passage 3 (P3) and P5 by Flow Cytometric Technique
CD Markers Fresh SVF CD markers P3 ADSCs P5 ADSCs
CD34+/CD10+ 2% CD34−/CD10+ 38% 28%
CD34+/CD13+ 90% CD34−/CD13+ 100% 99%
CD34+/CD14+ 5% CD34−/CD14+ 0% 0%
CD34+/CD29+ 100% CD34−/CD29+ 98% 96%
CD34+/CD31+ 61% CD34−/CD31+ 1% 2%
CD34+/HLA-DR+ 3.5% CD34−/CD45+ 0.5% 0.2%
CD34+/CD49+ 42% CD34−/CD49+ 2% 3%
CD34+/CD73+ 100% CD34−/CD73+ 94% 94%
CD34+/CD105+ 100% CD34−/CD105+ 87% 88%
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ischemic limbs of low- or high-dose TFC group animals 
compared to the placebo control group were evident as 
early as 1 week following treatment (day 14 of the study). 
The effect was significant in the group receiving the 
highest dose of TFC [58.5 ± 24.3 relative perfusion units 
(RPU)] versus the placebo control group (30.5 ± 15.1 
RPU) at day 35 following surgery, which was 1 month 
after treatment. The level of perfusion at day 35 in the 
treated limb of the high-dose group was not different 
compared to that in the sham group (54.3 ± 15.4 RPU) 
(Fig. 4).
Enhanced reperfusion in the high-dose TFC group cor-
related with greater capillary density in the treated mus-
cles. Histological analysis of CD31+ endothelial cell density 
in the gastrocnemius muscle of all animals in the study 
was performed (Fig. 5A). The ischemic (index) limbs of 
animals treated with high-dose TFC (23.91 ± 12.82) pos-
sessed significantly higher capillary density (p < 0.01) 
compared to the nonischemic control limb (18.41 ± 11.36) 
(Fig. 5B). Capillary density in the index limbs of the high-
dose TFC group (8.41 ± 12.82) was also greater (p < 0.05) 
than in the placebo group (3.32 ± 12.19), respectively 
(Fig. 5C).
The increased capillary density leading to enhanced 
muscle perfusion in the high-dose-treated group corre-
lated with increased levels of angiogenic factors in the 
circulation. Analysis of blood samples collected at dif-
ferent time points revealed that rabbits treated with either 
high- and low-dose TFC had transiently higher blood 
levels of rabbit VEGF (p < 0.05) compared to levels in 
blood of the placebo group at 1 week following treatment 
(Fig. 6). Rabbit serum levels of VEGF at 1 week follow-
ing treatment (day 14 of the study) were 60.9 ± 33.4 pg/ml 
(placebo control), 141 ± 70.7 pg/ml (high-dose TFC), and 
142.5 ± 96 pg/ml (low-dose TFC). Circulating levels of 
HGF and bFGF were also higher following treatment with 
TFC compared to the placebo control group, although the 
effect was not significant at all time points.
DISCUSSION
This study demonstrated that factors secreted by 
ADSCs in culture and delivered as a single intramuscu-
lar bolus to the affected limb promoted revascularization 
of ischemic skeletal tissue in a rabbit model of subacute 
PAD. The rationale for using TFC is based on an increas-
ing recognition that the salutary effects of adult stem/
progenitor cells are a function of paracrine factors as 
opposed to direct tissue regeneration through transdiffer-
entiation9. These factors have the potential to stimulate 
endogenous repair, modulate inflammation, and pro-
mote survival of at-risk tissues11. TFC contains factors 
involved in each of these processes. For instance, the pro-
survival and potent angiogenic factor VEGF was present 
in TFC at levels that were 46-fold higher than detected 
in human serum. Importantly, for skeletal muscle protec-
tion and recovery from ischemia, TFC contained high 
levels of the anti-inflammatory myocyte cytokine IL-625. 
Furthermore, the exposure of ischemic tissues to the fac-
tors contained in TFC produced a systemic increase in 
levels of the prosurvival angiogenic factor VEGF. The 
angiogenic and prosurvival factors HGF and bFGF were 
Figure 2. Outgrowth of adipose-derived stem cells (ADSCs) 
from SVF. Morphology of cultured ADSCs. Photomicroscopic 
image of cultured ADSCs at passage 3. Scale bar: 50 mm.
Table 3. Analysis of Selected Proteins Levels 
in 50-Fold Concentrated Therapeutic Factor 
Concentrate (TFC) and in Human Serum 
From a Healthy Donor
Cytokine huTFC huSerum
IFN-g <10.0 <10.0
IL-10 <3.0 <3.0
IL-12 p70 <1.0 <1.0
IL-13 4.9 10.1
IL-1b <2.0 2.6
IL-2 <5.0 <5.0
IL-4 5.0 0.9
IL-6 369.0 3.0
IL-7 0.2 41.2
IL-8 36.8 2.2
MMP-9 271.0 15,602.0
TNF-a 131.0 130.0
aFGF 439.0 2,541.0
IGF-I <0.1 <0.1
PDGF-AA 159.0 12,530.0
TGF-b1 4,296.0 13,924.0
VEGF 7731.0 186.0
All values are expressed as pg/ml. <: below detec-
tion limit.
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Figure 4. TFC treatment enhances ischemic limb perfusion. A laser Doppler probe was used to serially measure perfusion (expressed 
as relative perfusion units) at the medial aspect of the ischemic limb gastrocnemius muscle. Each symbol represents the gnostic median 
value for a group on the indicated days. Vertical lines represent standard deviations. Values for “preop” and “postop” were obtained 
on the first day of the experiment immediately before and after, respectively, the surgery to induce unilateral hindlimb ischemia. Filled 
box, sham control; open box, placebo control; filled circle, low-dose TFC; open circle, high-dose TFC. *p < 0.05.
Figure 3. (A) Validation of the rabbit critical limb ischemia model used in this study. (A) Surgical procedure of induction of acute hindlimb 
ischemia (HLI) in rabbits. The superficial femoral artery and vein were ligated and excised. (A) Common femoral artery, (B) dissected 
superficial femoral artery, (C) femoral nerve, and (D) branching popliteal artery. (B) Box and whisker plot comparing serial laser Doppler 
perfusion of the sham (white) and placebo control (gray) groups. The median of relative perfusion units (RPU) for each day of measurement 
is represented by a horizontal line in the box; the lower and upper boundaries of the box are the 25th and 75th percentiles, respectively. The 
whiskers extend to the most extreme data points not considering outliers, which are plotted as the filled circles.
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also elevated following treatment. Thus, a single admin-
istration was sufficient to induce recovery over the dura-
tion of the study.
It has been postulated that therapeutic cells differen-
tially home to the injury site and respond to the host envi-
ronmental cues; thus, the cells produce a concentrated 
combination of factors that are optimized to address a 
particular disease state11. However, there is scant in vivo 
experimental evidence to support this hypothesis, and at 
least one study demonstrated that paracrine factors act-
ing at a distal from the lesion could be responsible for 
the majority of the beneficial effects following treatment 
with BM-MSCs26. This study found that the vast majority 
of intravenously administered BM-MSCs were trapped in 
the lung, where they persisted with a half-life of 24 h and 
released factors that promoted protection from myocar-
dial infarction. Even with direct injection to the injury 
site, the frequency of cellular retention is quite low and 
the retention time of all but the rare population of cells 
that engraft long term is extremely short (with half-
lives of a few hours)21,22. Thus, the period of exposure 
to the environment would appear to be too brief to allow 
for effective modulation of the paracrine factor profile 
secreted by those few cells that homed to the injury site, 
although the exact kinetics of clearance would depend on 
the route of delivery.
There are several advantages of an ex vivo-derived 
cocktail of the factors produced by therapeutic cells over 
administering cells themselves. As opposed to treatment 
with cells, direct injection of TFC provides a bolus of 
“ready-made” paracrine factors that are immediately 
available to alter the pathophysiological process. We 
and others have found that TFC produced using stan-
dard cell culture conditions possesses robust activity in 
ischemic models17–20. By varying the physiochemical envi-
ronment used in culture, it is possible to modify the fac-
tors expressed by the cells, which allows for producing 
disease-specific combinations of factors. Furthermore, 
the composition of TFC can be carefully characterized 
and tested in order to ascertain the levels of each factor 
contained within. TFC can also be tested for safety and 
efficacy before administration. Conversely, the response 
of a cell to the complex host environment after local or 
systemic delivery is difficult to predict with respect to 
composition of secreted factors, as well as those released 
through cell lysis. Finally, it is becoming apparent that, 
although they possess some degree of immunoprivilege, 
allogeneic MSCs do evoke an immune response that may 
limit repeated administration27,28. Conversely, the proteins 
in CM are less likely to stimulate an immune response, 
which would allow repeated administration in order to 
enhance the response.
On the basis of the results of this preclinical study, we 
believe that TFC could be potentially efficacious in CLI 
patients. We envision an off-the-shelf product that would 
be immediately available for administration with little 
preparation. To this end, we are planning a clinical trial 
with patients who are not candidates for conventional 
revascularization. If successful, TFC could increase the 
quality of lives and reduce morbidity, such as amputation, 
for a significant patient population that is not currently 
eligible for or helped by conventional therapy.
Figure 5. TFC induces increased capillary density in the ischemic leg. Capillary densities in the gastrocnemius muscles at 5 weeks 
following surgically induced ischemia. (A) Representative image of a cross section of the gastrocnemius muscle in the ischemic 
hindlimb that had been immunohistochemically stained for CD31 antigen (marker of endothelial cells). Scale bar: 20 mm. (B) A box 
and whisker plot of capillary density (counts of CD31+ cells) in the high-dose TFC group for untreated, nonischemic limb (filled box) 
versus ischemic limb treated with high-dose TFC (open box). (C) A box and whisker plot of capillary density (CD31+ cell count per 
10 mm2) in the ischemic limb of the placebo group (filled box) versus ischemic limb of the high-dose TFC group (unfilled box). 
Median of control limbs was subtracted from ischemic limb values to equalize baselines between the two groups. Description of box 
plots provided in Figure 3. *p < 0.05; **p < 0.01.
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